Skip to main content

Table 3 Pharmacokinetic analysis of erlotinib in Schedule A patients

From: A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

  13 14 15 16 17 18
Erlotinib alone (day 6)
 AUC (μM) 23.45 29.68 45.44 46.19 13.87 50.14
 Cmax (μM) 2.17 1.83 2.73 2.97 0.86 3.42
 Tmax (h) 6 6 8 8 8 8
 t 1/2 (h) 7.1 25.7 18.1 15.1 15.4 9.4
Erlotinib (+rosuvastatin) (day 14)
 AUC (μM) off study 34.32 62.74 59.51 21.22 24.81
 Cmax (μM) off study 1.96 3.95 3.90 1.19 1.57
 Tmax (h) off study 8 6 10 10 8
 t1/2 (h) off study 24.3 14.5 12.8 12.8 13.3